8-K: Hims & Hers Acquires Eucalyptus for $1.15B, Eyes Global Health Leadership

Hims & Hers Health, Inc. announced a definitive agreement to acquire Eucalyptus, an international digital health leader, for up to $1.15 billion to accelerate global expansion.

Summary

• Hims & Hers Health, Inc. (HIMS) is acquiring EUC Management Pty Ltd (d/b/a Eucalyptus), an Australia-based digital health company, for an aggregate consideration of up to approximately $1.15 billion.
• Eucalyptus operates in Australia, the UK, Germany, Canada, and Japan, and has served over 775,000 customers.
• The acquisition consideration includes approximately $240 million in upfront cash payments, $710 million in deferred payments, and up to $200 million in earnout payments tied to revenue and adjusted EBITDA targets through fiscal years 2026-2028.
• Hims & Hers has the option to settle the majority of deferred and earnout payments in cash or its Class A common stock.
• The transaction is expected to close in mid-2026, subject to customary closing conditions, including regulatory approvals.
• Eucalyptus currently has an annual revenue run-rate (ARR) north of $450 million USD and achieved triple-digit year-over-year ARR growth in each quarter of calendar year 2025, operating within line of sight of profitability.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly strategic and positive move, significantly expanding Hims & Hers' global footprint and market potential, despite inherent integration and earnout risks.

Positives

• Accelerates Hims & Hers' vision to become a leading global consumer health platform.
• Expands Hims & Hers' presence into new markets (Australia, Japan) and deepens existing ones (UK, Germany, Canada).
• Adds Eucalyptus's expertise in efficient market entry, clinical rigor, digital experience, and local regulatory knowledge.
• Eucalyptus has a strong customer base, having served over 775,000 customers.
• Eucalyptus's annual revenue run-rate (ARR) is north of $450 million USD, demonstrating significant scale.
• Eucalyptus achieved triple-digit year-over-year ARR growth in each quarter of calendar year 2025, indicating strong momentum.
• The acquisition is expected to drive category leadership for Hims & Hers in Australia and establish it as a leading telehealth provider in the UK and Germany within two years.
• The transaction structure preserves financial flexibility, with an option to settle a majority of deferred and earnout payments in stock, and financing primarily from existing cash and future operating cash flows.
• Tim Doyle, Eucalyptus CEO, will join Hims & Hers as SVP of International, bringing valuable leadership and expertise.
• The deal is expected to strengthen commercial relationships and create new opportunities for collaborations with biotech innovators, diagnostic companies, and drugmakers.

Negatives

• The acquisition involves a significant aggregate consideration of up to $1.15 billion, which could impact Hims & Hers' balance sheet depending on the mix of cash and stock used.
• Integration of Eucalyptus's portfolio of brands into Hims & Hers will occur over time, which can be a complex process.
• The earnout payments are contingent on achieving specific revenue and adjusted EBITDA targets, introducing performance-based risk.

Risks

• The Proposed Acquisition may not be consummated in a timely manner, if at all.
• Diversion of management's attention from Hims & Hers' ongoing business operations.
• Potential negative effects of the acquisition announcement on Eucalyptus's and Hims & Hers' business relationships (customers, suppliers).
• Risks related to the integration of the Eucalyptus business and Hims & Hers' international expansion.
• Risks related to obtaining requisite consents, including timing and receipt of regulatory approvals from governmental entities (which may include conditions, limitations, or restrictions), and the risk that approvals may be denied.
• Regulatory, compliance, and legal risks in the jurisdictions where Hims & Hers operates, including evolving regulatory frameworks.
• Risks related to Hims & Hers' liquidity and capital allocation, including unanticipated demands on cash resources or changes in operating performance.

Future Outlook

Hims & Hers anticipates that the acquisition of Eucalyptus will significantly accelerate its global expansion, enabling it to become a leading global consumer health platform. The company expects to achieve category leadership in Australia and establish itself as a leading telehealth provider in the UK and Germany within the next two years. This expansion is also projected to strengthen commercial relationships and foster new collaborations with biotech innovators, diagnostic companies, and drugmakers. The integration of Eucalyptus's capabilities is expected to expand offerings and enhance access to personalized care globally, while maintaining high quality and safety standards.

Management Comments

• "Healthcare challenges are global, and so is the demand for simpler, transparent, and more personalized healthcare. But how that comes to life looks different for every region and every person. We’ve shown the difference that makes in the US, and the logical next step is working with more international experts to make that difference abroad." Andrew Dudum, founder and CEO of Hims & Hers.
• "With Eucalyptus, we will not only enter new markets, we will expand our ability to serve customers globally, trusting local experts to be a key part of how we transform healthcare into a customer-first, personalized industry. We believe this puts us on the path to becoming the leading global consumer health platform, where everyone can access the best care for their needs, regardless of where they live." Andrew Dudum.
• "By joining Hims & Hers, we will help more people globally believe in the future of healthcare: simple, high-quality, personal, and designed to help prevent disease, instead of merely treating it." Tim Doyle, co-founder and CEO of Eucalyptus.
• "We’ve spent 7 years helping customers around the world find the care that fits them, and we believe today’s news will be part of accelerating the movement towards affordable healthcare for everyone that feels like a luxury. We’re thrilled to join Andrew and the whole Hims & Hers team and work toward this new future together." Tim Doyle.

Industry Context

StockSavvy.ai notes that this acquisition positions Hims & Hers to capitalize on the growing global demand for digital health and personalized healthcare solutions. The move aligns with a broader industry trend of telehealth providers seeking international expansion to diversify revenue streams and tap into underserved markets. By acquiring Eucalyptus, a company with a proven track record in multiple international markets and strong clinical rigor, Hims & Hers is strategically enhancing its competitive standing against other global digital health players and traditional healthcare providers adapting to digital transformation. The emphasis on local expertise and regulatory compliance is crucial for successful international market penetration in a highly regulated sector.

Comparison to Industry Standards

• Eucalyptus's reported annual revenue run-rate (ARR) north of $450 million USD and triple-digit year-over-year ARR growth in 2025 suggest a strong performance relative to many emerging digital health companies, indicating a robust and rapidly scaling business.
• Its accreditation from the Australian Council on Healthcare Standards (ACHS) against EQuIP6 standards for safety and quality of clinical services sets a high benchmark, comparable to leading healthcare quality accreditations globally, and demonstrates a commitment to clinical excellence that can be leveraged by Hims & Hers.
• The acquisition value of up to $1.15 billion for a company with over $450 million ARR implies a valuation multiple that reflects Eucalyptus's high growth and market leadership in its operating regions, aligning with valuations seen for high-growth digital health assets in competitive M&A environments.
• The strategy of using a mix of upfront cash, deferred payments, and earnouts is a common practice in large acquisitions, allowing Hims & Hers to manage cash flow while incentivizing Eucalyptus's former owners and management to achieve future performance targets, a structure often seen in deals involving rapidly growing, founder-led companies.

Management Changes

Corporate Governance

Legal Proceedings

• The filing mentions "no Claim threatened in writing to a Target Group Member or, so far as the Vendors are aware, pending against a Target Group Member" (Warranty 11.1(a)).
• It also states "no action, order, judgement or determination pending, threatened or anticipated, against a Target Group Member" (Warranty 11.1(c)).
• The forward-looking statements section lists "regulatory, compliance and legal risks in the jurisdictions where the Company operates, including evolving regulatory frameworks" as a risk.

Related Party Transactions

• Other than in respect of contracts or arrangements of employment, no Target Group Member is party to any contract with any Vendor Party or any of its Representatives, or in which any Vendor Party or any of its Representatives is interested (whether directly or indirectly) or under which a Target Group Member has given or proposes to give a financial benefit to any Vendor Party or any of its Representatives.
• There are no guarantees, indemnities, contracts, loans, commitments, arrangements or understandings in respect of a Target Group Member and a Vendor Party or any of its Representatives.

Stakeholder Impact

• Shareholders (Hims & Hers): Potential for significant international growth and market leadership, but also dilution risk if stock is used for payments and integration risks.
• Shareholders (Eucalyptus): Will receive substantial consideration (cash and potentially Hims & Hers stock) for their equity.
• Employees (Eucalyptus): Certain employees will receive restricted stock unit awards and will join Hims & Hers, indicating retention and integration into the larger company. Tim Doyle, CEO, will take a key international leadership role.
• Customers (Eucalyptus/Hims & Hers): Expected to benefit from expanded access to high-quality, personalized care and a diversified range of offerings globally.
• Suppliers/Partners: The deal is expected to strengthen commercial relationships and create new opportunities for collaborations with biotech innovators, diagnostic companies, and leading drugmakers.
• Creditors: The negotiation of a $30 million revolving debt facility for Eucalyptus prior to closing, subject to Hims & Hers' existing credit agreement, indicates potential impact on credit lines.

Next Steps

• Closing of the Proposed Acquisition, anticipated during the middle of fiscal year 2026.
• Satisfaction of customary closing conditions, including regulatory approvals and key contract consents.
• Integration of Eucalyptus's portfolio of brands into Hims & Hers over time.
• Tim Doyle, current CEO of Eucalyptus, will transition to SVP of International at Hims & Hers.
• Hims & Hers will grant restricted stock unit awards to certain Target employees joining the company.
• Purchaser and Target will negotiate a revolving debt facility for Target's working capital needs prior to Closing.
• Hims & Hers will file a registration statement for resale of Company Shares issued via the Equity Option, if necessary.
• Hims & Hers will work towards achieving category leadership in Australia and becoming a leading telehealth provider in the UK and Germany within the next two years.

Key Dates

Recommendation

This acquisition represents a highly strategic and transformative move for Hims & Hers, significantly accelerating its international expansion and positioning it as a leading global consumer health platform. Eucalyptus brings a proven model, substantial ARR (north of $450 million USD with triple-digit growth), a large customer base, and critical local expertise in key growth markets. The deal structure, with a significant portion of deferred and earnout payments, aligns incentives and manages upfront cash outlay, while the option for stock settlement provides financial flexibility. The integration of Eucalyptus's clinical rigor and market penetration capabilities, combined with Hims & Hers' existing platform, creates a compelling long-term growth trajectory and strengthens its competitive advantage in the rapidly expanding digital health sector. The appointment of Eucalyptus's CEO to a key international role further de-risks integration and ensures continuity of expertise.

Keywords

Hims & Hers, Eucalyptus, Acquisition, Digital Health, Telehealth, International Expansion, Healthcare Platform, Merger, SEC Filing, HIMS, Australia, UK, Germany, Canada, Japan, Consumer Health, Earnout, Deferred Payments, Regulatory Approvals